Lit Matters 1: GU swab vs. Urine for STI Detection

Vaginal NAAT swabs are more sensitive than urine for detecting chlamydia, gonorrhea, and trichomonas in women. CDC guidance already prefers vaginal swabs, but the real emergency-department question is whether a modest diagnostic gain justifies changing workflow, specimen collection, and screening practice.

Swab Versus Urine for STI NAATs

• Sensitivity advantage of swabs: Vaginal swabs outperformed urine across all three infections, with the clearest gap in chlamydia detection at 94.1% versus 86.9%, reinforcing why swabs remain the preferred female specimen.
• CDC specimen preference: CDC guidance favors vaginal swabs as the primary collection method for women, aligning practice with the best-performing FDA-cleared NAAT specimen type rather than defaulting to urine.
• Clinical size of the gap: The difference is real but modest: gonorrhea sensitivity was 96.5% for swabs versus 90.7% for urine, while trichomonas showed a smaller, non-significant separation.
• Workflow versus yield: Patient-obtained vaginal swabs may improve flow by allowing collection right after registration, but whether that gain is enough to fully replace urine testing is the practical tension we get into in the episode.
• Specimen collection mechanics: Urine STI testing is only as good as the specimen quality, and a clean-catch sample is the wrong collection method for NAAT detection, creating an easy bedside source of false reassurance.
• ED practice question: This meta-analysis answers assay sensitivity, not how often symptomatic ED patients are truly missed or whether every screening encounter warrants an invasive exam; that distinction is worth hearing in the chapter.